<DOC>
	<DOC>NCT00254267</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.</brief_summary>
	<brief_title>Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis of histological confirmed GIST Had prior imatinib mesylate therapy Has at least 1 measurable leasion by modified RECIST Central nervous system tumor involvement requiring treatment History of myocardial infraction Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Gastrointestinal Stromal Tumor, Imatinib Mesylate Resistance, Phase2 study, AMG 706</keyword>
</DOC>